Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revottack + Toripalimab in Advanced Solid Tumors
NCT05644509Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor (advanced stage), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Incidence of adverse events up to 6 months, Objective response rate up to 2 years and 6 more. Status: unknown.
02
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05644509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644509.